Edition:
United Kingdom

Bioton SA (BIOP.WA)

BIOP.WA on Warsaw Stock Exchange

5.60PLN
3:59pm GMT
Change (% chg)

-0.06zł (-1.06%)
Prev Close
5.66zł
Open
5.66zł
Day's High
5.75zł
Day's Low
5.57zł
Volume
26,098
Avg. Vol
84,178
52-wk High
7.65zł
52-wk Low
3.13zł

Summary

Name Age Since Current Position

Jubo Liu

2017 Chairman of the Supervisory Board

Robert Neymann

2017 Chairman of the Management Board

Dariusz Trzeciak

2017 Vice Chairman of the Supervisory Board

Vaidyanathan Viswanath

2018 Vice Chairman of the Supervisory Board

Marek Dziki

55 2016 Member of the Management Board

Boguslaw Kocinski

2017 Member of the Management Board

Adam Polonek

2011 Member of the Management Board

Qi Bo

2017 Member of the Supervisory Board

Mark Chiang

2017 Member of the Supervisory Board

Gary He

2017 Member of the Supervisory Board

Katarzyna Sadowska

2018 Investor Relations Contact Officer

Biographies

Name Description

Jubo Liu

Dr. Jubo Liu has served as Chairman of the Supervisory Board of Bioton S.A. since May 15, 2017. He has previously been Chairman of the Management Board since November 26, 2016. He was Chairman of the Supervisory Board and Acting Chairman of the Management Board of the Company from October 4, 2016. Prior to that, from February 23, 2016 he was Chairman of the Supervisory Board at the Company. He was Member of the Supervisory Board of the Company from February 22, 2016. He has been Vice Chairman of the Audit Committee of the Company since May 15, 2017. He is founder and Chairman of Cogenes Biotechnology Incorporation, as well as founder of NovoTek Pharmaceuticals Limited and Beijing NovoTek Medicinal Technology Development Co. Ltd. During his professional career, he served at Immtech Pharmaceuticals Inc., Pharmaceuticals Inc., Boston Vertex Pharmaceuticals Inc. and Beijing Huayuanlong Medicinal Technology Development Co. Ltd. He holds Bachelor’s degree in Pharmacy from Shenyang Pharmaceutical University and Ph.D. degree from University of Toronto.

Robert Neymann

Mr. Robert Neymann has been Chairman of the Management Board at Bioton S.A. since May 15, 2017. He studied Finance at Szkola Glowna Handlowa from 1982 till 1987. He was Financial Controller, Head of Blendax Sales Division in Poland at OMC Poll Ltd. (1987-1990), National Key Account Manager at Procter & Gamble Polska (1990-1991), Unit Sales Manager (Northern Poland) at Procter & Gamble Polska (1991-1993), Trade Marketing Manager at Procter & Gamble Polska (1993-1994), among others. He was also Vice Chairman of the Management Board for Commercial at Herbapol Lublin S.A. (2001-2005), Chairman of the Management Board of Polsnack sp. z o.o., Harper Trade sp. z o.o. and Harper Hygienics S.A.

Dariusz Trzeciak

Mr. Dariusz Trzeciak has been Vice Chairman of the Supervisory Board of Bioton S.A. since May 15, 2017. He was Chairman of the Supervisory Board from November 26, 2016 till May 15, 2017. He was Vice Chairman of the Supervisory Board of the Company from September 22, 2015. He was Member of the Supervisory Board the Company from September 21, 2015. Prior to that, he was Vice Chairman of the Supervisory Board of the Company from 2014. Prior to that, he served as Member of the Supervisory Board of the Company from June 24, 2013. He has been Chairman of the Company's Audit Committee. Moreover, he has served as Member of the Management Board of Sferia SA, Chairman of the Supervisory Board of Polskie Media SA and Vice Chairman of the Supervisory Board at Radio PIN SA. In the past, he held managerial and supervisory positions in the companies such as Towarzystwo Ubezpieczen na Zycie Polisa Zycie SA where he was Chairman of the Management Board, Sferia SA and IT Popager SA. He completed four-year doctorate studies at Uniwersytet Warszawski, postgraduate studies in International Business Management at Szkola Glowna Handlowa w Warszawie and Faculty Law and Administration and Faculty of History at Uniwersytet Warszawski.

Vaidyanathan Viswanath

Mr. Vaidyanathan Viswanath has been Vice Chairman of the Supervisory Board of Bioton S.A. since March 22, 2018. He was Member of the Supervisory Board of the Company from June 28, 2016. He served at Serum Institute (Serono) and Astra in India, at Pharmacia in India, at Pfizer China and at Capsugel.

Marek Dziki

Dr. Marek Dziki has been Member of the Management Board of Bioton S.A. since February 24, 2016. He graduated from Uniwersytet Medyczny w Lublinie as a doctor of medicine and obtained an MBA degree from Miedzynarodowa Szkola Biznesu w Warszawie. He is Chairman of M&M Pharma and consultant at Lumeden, where he served as General Director from 2013 to 2014. During his professional career, he also served at Centrum Innowacji Skolkovo, Merck Limited, Merck Darmstadt, Merck Austria, Merck Polska and Merck Poland.

Boguslaw Kocinski

Mr. Boguslaw Kocinski has served as Member of the Management Board at Bioton S.A. since December 12, 2017. He graduated from Politechnika Warszawska and Szkola Glowna Handlowa w Warszawie. He joined the Company in 2010 as Director of Operations. From 2008 to 2010 he served at Pepsi Cola General Bottlers as Production Director and Member of the Management Board. From 2007 to 2008 he was Director of Operations at Trinity Management, from 2001 till 2005 he served as Proxy and Director of Browar Warka at Zywiec S.A. Group. From 1996 to 2001 he served at Eli Lilly and from 1987 to 1995 at HTL.

Adam Polonek

Mr. Adam Tomasz Polonek has been Member of the Management Board at Bioton S.A. since December 20, 2011. He has also been Non-Executive Director of SciGen Ltd since June 26, 2008. Mr. Polonek joined Bioton in 2006 as Deputy Finance Director and since April 2009 as the Finance Director. He has held the position of Deputy Finance Director of Bioton Trade Ltd and has acted as Member of the Board of BioPartners Polska Ltd, which are part of the Bioton Group. Mr. Polonek’s professional experience includes career in an investment bank in CEE Europe and CAIB Financial Advisers (currently UniCredit CAIB Poland). During his career, he was involved in several Corporate Finance transactions and he has experience in stock exchange markets. He graduated from Uniwersytet Ekonomiczny w Katowicach.

Qi Bo

Mr. Qi Bo has been Member of the Supervisory Board at Bioton S.A. since September 29, 2017. Mr. Qi Bo has over twenty-five years of proven track record of achievement in biopharmaceutical companies in US and China, with solid knowledge and experience in pharmaceutical drug lifecycle including process development, validation, technology transfer, manufacturing and regulatory filing. He worked on multiple world-wide approved recombinant protein/monoclonal antibody products, e.g. Aranesp (Amgen), Erbitux (ImClone) and Cyramza (Lilly) and Portrazza (Lilly). He has worked as Genron corporation, CHINA/Vice President and Head of CMC, General Manager of Generon Beijing Plant (2015-Present). Previously, he was employed at Eli Lilly and Company (NJ), US/ Director of CMC Development (2008-2015); ImClone System Inc., NJ, US/Director of Process Development (2002-2008); Amgen Inc., CA, US /Associate Scientist of Process Development (1992-2002). He holds M.Sc. in Biochemistry, University of Minnesota, US (1988-1991) and B.Sc. in Biochemistry, East China Univ. of Sci & Tech, China (1980-1984).

Mark Chiang

Mr. Mark Ming-Tso Chiang has been Member of the Supervisory Board at Bioton S.A. since May 15, 2017. He holds a Ph.D. in Computer Science from University of London. He worked as analyst for over five years. Since 2009 he has worked with international pharmaceutical companies.

Gary He

Mr. Gary He has been Member of the Supervisory Board at Bioton S.A. since September 29, 2017. Mr. Gary He has been Vice President of CMC Global Compliance at Generon Corporation Ltd. since Nov. 2016. From April 2004 to Oct 2016 he was an Associate Director at Eli Lilly & Company (US New Jersey) (served as a member of the Site Management Team, the Change Board, the Quality Board, and the Engineering Team to manage the site wide production and quality activities). From September 2001 to April 2004, he acted as a senior consultant at Bristol-Myers Squibb (US New Jersey). From April 1995 to August 2001 he was a senior engineer at Lockwood Greene Engineering (US New Jersey). From January of 1994 to January of 1995 he was a validation engineer at Qualis Inc. (US Iowa). From August 1984 to February 1990, he served as a project engineer/product supervisor at No. 3 Pharmaceutical Company in Shanghai. Mr. He obtained his Bachelor's Degree in Biochemical Engineering from East China Technical Institute, Shanghai, P.R. China (from September 1980 to July 1984) and a Master's Degree in Chemical Engineering from Wayne State University, Michigan (from September 1990 to September 1993).

Katarzyna Sadowska

Basic Compensation

Name Fiscal Year Total

Jubo Liu

310,000

Robert Neymann

640,000

Dariusz Trzeciak

40,000

Vaidyanathan Viswanath

24,000

Marek Dziki

1,156,000

Boguslaw Kocinski

34,000

Adam Polonek

1,111,000

Qi Bo

6,000

Mark Chiang

15,000

Gary He

6,000

Katarzyna Sadowska

--
As Of  31 Dec 2017